Robot-assisted radical prostatectomy is a minimally invasive way to perform the same cancer operation as a radical prostatectomy: the prostate and usually the seminal vesicles are removed, the bladder is reconnected to the urethra, and lymph nodes may be removed when indicated. The robot does not operate autonomously. A surgeon controls the camera and articulated instruments from a console. Robotic assistance can reduce blood loss, transfusion and hospital stay compared with open surgery in many studies and may accelerate early functional recovery, but it does not eliminate urinary incontinence, erectile dysfunction, positive surgical margins, recurrence or the need for additional treatment.
Robotic prostatectomy is best understood as a surgical platform, not a different cancer treatment. It gives the surgeon magnified three-dimensional visualization and wristed instruments through small abdominal ports, but the oncological goals remain complete cancer removal, safe nerve preservation when appropriate, accurate lymph-node staging when indicated and a watertight bladder-to-urethra reconstruction. Current evidence generally favors robotic surgery for lower blood loss and shorter hospitalization, while long-term cancer control, continence and erectile outcomes depend heavily on disease biology, surgical technique and surgeon/program performance.
01How Is a Robotic Prostatectomy Performed?
The surgeon controls the robot throughout the operation
Robot-assisted radical prostatectomy is performed under general anesthesia.
The operating surgeon sits at a surgical console and controls:
- a high-definition three-dimensional camera;
- articulating surgical instruments;
- energy devices used for dissection and bleeding control;
- and the movements needed to remove the prostate and reconstruct the urinary tract.
A bedside surgical team positions instruments, exchanges devices, manages suction and assists with the operation.
Does the robot perform any part of the surgery automatically?
No.
The term “robotic” can be misleading.
Current surgical robots are surgeon-controlled systems. The surgeon’s movements are translated to instruments inside the patient. The platform can filter tremor, scale movement and allow wrist-like articulation, but it does not independently decide where to cut, whether to spare a nerve or whether a margin is safe.
How does the surgeon reach the prostate?
Most robot-assisted prostatectomies use several small abdominal ports.
A typical setup includes:
- a camera port;
- robotic instrument ports;
- and one or more assistant ports.
Some systems use a single access port through which multiple articulated instruments are introduced.
Why is the abdomen inflated with gas?
Carbon dioxide creates a working space inside the abdomen or pelvis. This pneumoperitoneum separates tissues and improves visualization.
The pressure can also reduce venous bleeding, but it alters normal physiology and is one reason robotic prostatectomy still requires general anesthesia and careful anesthetic monitoring.
What is Trendelenburg positioning?
During many robotic prostatectomies, the operating table is tilted so that the patient’s head is lower than the pelvis.
This moves abdominal organs away from the pelvis and improves surgical access.
However, prolonged positioning can contribute to:
- pressure-related nerve injury;
- facial or airway swelling;
- changes in eye pressure;
- and cardiopulmonary effects in susceptible patients.
What are the major steps once the robot is docked?
Technique varies, but standard steps include:
- expose the prostate and bladder neck;
- divide the bladder neck from the prostate;
- dissect the seminal vesicles and vas deferens;
- develop the posterior plane;
- control the dorsal venous complex;
- perform side-specific nerve sparing when oncologically safe;
- divide the urethra at the prostate apex;
- remove the prostate specimen;
- perform pelvic lymph-node dissection when indicated;
- and reconnect the bladder neck to the membranous urethra.
The complete oncological operation is explained in Radical Prostatectomy for Prostate Cancer.
What is Retzius-sparing robotic prostatectomy?
Standard approaches usually enter the space in front of the bladder called the space of Retzius.
Retzius-sparing robotic prostatectomy approaches the prostate from behind, preserving more of the anterior bladder and supporting structures.
EAU evidence suggests it can improve early continence recovery, but some studies report higher positive surgical-margin rates. It should therefore be viewed as a technical variation with trade-offs rather than as a universally superior robotic method.
What is single-port robotic prostatectomy?
Single-port systems place the camera and multiple flexible instruments through one main access site rather than several separate robotic ports.
A 2025 meta-analysis found advantages in some perioperative measures such as pain, blood loss, hospital stay and catheter removal, while continence, potency, complications, positive margins and biochemical recurrence were broadly similar to multi-port surgery.
The evidence is still evolving, and the platform should not be used as a proxy for surgical quality.
“Robotic” describes how the surgeon reaches and manipulates the prostate—not what is removed. A robot-assisted radical prostatectomy should still remove the intended oncological specimen, preserve nerves only when safe, reconstruct the urinary tract and achieve appropriate nodal staging when indicated.
02Who Is Considered for Robotic Prostatectomy?
The cancer indication comes before the choice of surgical platform
A patient should first be an appropriate candidate for radical prostatectomy.
Only then does the question become whether the operation will be performed robotically, laparoscopically or through an open approach.
Selection depends on:
- clinical stage and prostate-cancer risk;
- Grade Group, PSA and imaging;
- life expectancy and comorbidity;
- fitness for general anesthesia and pelvic surgery;
- baseline urinary and erectile function;
- prior prostate, abdominal or pelvic surgery;
- prostate size and anatomy;
- need for pelvic lymph-node dissection;
- and informed preference after comparison with surveillance and radiation.
Which disease stages are commonly treated robotically?
Robot-assisted prostatectomy is used mainly for selected nonmetastatic prostate cancer:
- clinically significant localized disease;
- selected intermediate-risk disease;
- selected high-risk localized disease;
- and selected locally advanced cases as part of a multimodal treatment strategy.
It is not standard therapy for established distant metastatic prostate cancer.
Should low-risk prostate cancer be removed robotically because the surgery is minimally invasive?
Not automatically.
A less invasive access route does not eliminate the long-term consequences of removing the entire prostate.
Suitable low-risk cancers are often better managed with active surveillance because the central question is whether treatment is needed—not how small the incisions can be.
Can a large prostate be removed robotically?
Yes.
Large prostate volume can increase technical complexity, but it does not automatically preclude robot-assisted surgery.
Current EAU evidence recognizes prostate size, obesity and previous transurethral prostate surgery as factors that can make radical prostatectomy more difficult and can affect perioperative or functional outcomes.
Can prior abdominal surgery prevent robotic prostatectomy?
Not necessarily.
Previous surgery can cause adhesions or alter anatomy, which may increase complexity. The choice depends on the previous operation, location of scars, radiation history, surgeon experience and whether an intraperitoneal, extraperitoneal or alternative access route is feasible.
Who may not tolerate the standard robotic position well?
Some patients with severe cardiopulmonary disease, significant glaucoma or other conditions affected by prolonged head-down positioning and pneumoperitoneum may require additional anesthetic evaluation or a different surgical strategy.
The presence of a surgical robot does not broaden the oncological indication for surgery. A cancer that should be monitored rather than treated remains a surveillance cancer even if robotic surgery can technically remove it.
03Is Robotic Prostatectomy Better Than Open or Standard Laparoscopic Surgery?
Robotic surgery has clear perioperative advantages, but “better” depends on the outcome being measured
Comparisons should separate at least four outcome groups:
- perioperative recovery;
- urinary continence;
- sexual function;
- and oncological control.
What are the strongest advantages of robot-assisted surgery?
The most consistent advantages are perioperative.
Current evidence generally shows robot-assisted radical prostatectomy is associated with:
- less intraoperative blood loss;
- lower transfusion requirements;
- shorter hospital stay;
- smaller abdominal incisions;
- and in some datasets, fewer postoperative complications.
A 2026 meta-analysis restricted to randomized and prospective comparisons included 27 studies and 38,530 patients. Compared with open radical prostatectomy, robotic surgery was associated with substantially less blood loss, lower transfusion rates, shorter hospitalization and fewer postoperative complications.
Does robotic surgery clearly improve long-term urinary continence?
The evidence is mixed.
Some randomized trials show earlier continence recovery after robot-assisted surgery, while another randomized comparison found no significant urinary-function difference between robotic and open surgery during the first two years.
EAU evidence therefore supports a more precise conclusion:
robotic surgery can improve early functional recovery in some settings, but the operation does not guarantee better long-term continence for every patient.
Does robotic surgery clearly improve erectile function?
Some prospective and randomized evidence favors earlier erectile recovery with robot-assisted surgery, especially when nerve sparing is feasible.
However, erectile outcome depends strongly on:
- age;
- preoperative erectile function;
- vascular health;
- tumor location;
- unilateral versus bilateral nerve sparing;
- and the quality of the nerve-sparing dissection.
A robot cannot preserve a nerve that must be removed for cancer control.
Does robotic surgery reduce positive surgical margins?
Not reliably enough to use the platform alone as a quality guarantee.
Margin status depends on pathological stage, tumor location, nerve-sparing decisions, dissection plane and surgeon technique.
EAU randomized evidence comparing robotic with laparoscopic surgery found similar positive-margin and biochemical-recurrence outcomes. NCI also notes that functional outcomes between open, laparoscopic and robot-assisted radical prostatectomy can be similar.
What about newer 2026 evidence?
A 2026 prospective-study meta-analysis reported favorable perioperative and early functional results for robotic surgery and a lower biochemical-recurrence rate at 24 months.
That finding should be interpreted cautiously because biochemical recurrence is influenced by tumor risk, pathological stage, follow-up duration and differences between study populations. Longer randomized follow-up is still needed before concluding that the robotic platform itself provides superior long-term cancer control.
| Outcome | Robot-assisted prostatectomy | Open prostatectomy | Best interpretation |
|---|---|---|---|
| Blood loss / transfusion | Generally lower. | Generally higher. | One of the most consistent robotic advantages. |
| Hospital stay | Often shorter. | Often longer. | Depends partly on local discharge pathways. |
| Incisions | Several small ports or a single-port incision. | Larger lower-abdominal incision. | Access differs; the internal cancer operation is still radical prostatectomy. |
| Early continence | Some trials/meta-analyses favor faster recovery. | Can recover more slowly in some studies. | Definitions and surgeon technique vary; long-term differences may narrow. |
| Erectile recovery | Some evidence favors earlier recovery when nerve sparing is feasible. | Can be comparable in longer follow-up. | Baseline function and nerve preservation are major determinants. |
| Positive margins | Not consistently superior across randomized evidence. | Depends on stage and surgical technique. | Do not judge cancer control from the platform alone. |
| Biochemical recurrence | Generally comparable in long-term randomized comparisons; some newer meta-analyses favor RARP at shorter follow-up. | Generally comparable when surgery is oncologically equivalent. | Long-term cancer control requires risk-adjusted follow-up. |
The most defensible evidence claim is not “robotic surgery is always better.” The consistent advantages are less blood loss and shorter hospitalization; early continence or erectile recovery may improve in some studies. Long-term functional and oncological outcomes remain strongly dependent on patient selection, tumor biology and the surgical team.
04What Is Recovery Like After Robotic Prostatectomy?
Smaller incisions do not mean the internal operation is small
The abdominal wounds are smaller than with open retropubic surgery, but the same prostate gland has been removed and the same urinary reconstruction has been created.
Recovery therefore occurs on several timelines:
- anesthetic and surgical recovery;
- port-site healing;
- bladder-to-urethra anastomosis healing;
- catheter removal;
- urinary continence recovery;
- erectile recovery;
- and postoperative cancer surveillance.
How long is the hospital stay?
Hospital pathways vary substantially by country, centre, patient health and complications.
Robot-assisted surgery is generally associated with a shorter stay than open surgery, and some centres discharge selected uncomplicated patients within one day.
A published stay from another health system should not be treated as a guaranteed personal discharge time.
How long is the catheter kept?
The catheter remains until the bladder-to-urethra anastomosis has healed sufficiently.
Timing depends on:
- surgeon and centre protocol;
- whether the anastomosis was watertight;
- previous TURP or bladder-neck surgery;
- prostate anatomy;
- and evidence of postoperative urinary leakage.
Cystography is sometimes used before catheter removal in higher-risk situations, but EAU guidance does not support routine cystography for every uncomplicated patient.
When can normal activity resume?
Walking is usually encouraged early.
Return to driving, work, lifting, exercise and sexual activity depends on recovery, catheter status, pain medication, complications and the treating team’s instructions.
A desk-based job and heavy physical work do not have the same recovery demand.
Is urinary leakage still common after robotic surgery?
Yes.
The robotic route does not remove the continence challenge created by radical prostatectomy.
Early leakage is common after catheter removal, then usually improves over weeks and months.
Long-term continence rates vary considerably because studies use different definitions:
- no pads;
- zero or one safety pad;
- patient-reported bother;
- or formal questionnaire scores.
What affects continence recovery after RARP?
Important variables include:
- age;
- baseline urinary function;
- preoperative membranous urethral length;
- prostate size;
- previous TURP;
- obesity;
- sphincter and urethral preservation;
- nerve sparing;
- and surgeon technique.
What affects erectile recovery?
Robot assistance does not override the biological requirements for erections.
Recovery depends on:
- preoperative erectile function;
- age;
- diabetes and vascular health;
- tumor location;
- unilateral or bilateral nerve sparing;
- traction and thermal injury during dissection;
- and time since surgery.
Erectile recovery can take many months and may remain incomplete even after technically successful bilateral nerve-sparing surgery.
What are the specific perioperative risks of robotic surgery?
In addition to the general complications of radical prostatectomy, robotic surgery introduces risks related to:
- pneumoperitoneum;
- prolonged Trendelenburg position;
- pressure or positioning nerve injuries;
- port-site bleeding or hernia;
- and rare need for conversion to another surgical approach.
EAU guidance notes that positioning neuropathy has been reported in robotic prostatectomy, most often involving the lower limbs.
“Minimally invasive” refers mainly to the access route. It should not be interpreted as “minor surgery.” Robotic radical prostatectomy still creates a new bladder-to-urethra connection, removes ejaculation permanently and can affect continence and erectile function for months or longer.
05Does Robotic Prostatectomy Provide Good Cancer Control, and How Should a Program Be Evaluated?
Cancer control is measured by pathology and follow-up—not by the brand of robot
The most important oncological outcomes after robotic prostatectomy include:
- pathological stage;
- final Grade Group;
- surgical margin status;
- lymph-node status when dissection is performed;
- postoperative PSA;
- biochemical recurrence;
- need for salvage or adjuvant treatment;
- metastasis-free survival;
- and prostate-cancer-specific survival.
What is a positive surgical margin?
A positive margin means cancer reaches the inked edge of the removed specimen.
It is an important quality and prognostic measure, but it must be interpreted by pathological stage.
A program that reports one overall margin percentage without separating organ-confined and extraprostatic cancers can create a misleading comparison because advanced tumors are intrinsically more likely to reach a surgical boundary.
What should PSA do after robotic prostatectomy?
Exactly what it should do after any successful radical prostatectomy:
fall to an undetectable level.
The robotic platform does not change the biological meaning of postoperative PSA.
Does the type of robot determine cancer outcome?
Current evidence does not support treating one robotic brand as an independent guarantee of better oncological results.
A 2025 systematic review comparing the newer Hugo RAS system with the established da Vinci platform found broadly comparable perioperative, oncological and functional outcomes, although evidence remains relatively early for newer platforms.
Why does surgeon and hospital experience matter?
Robot-assisted prostatectomy has a learning curve.
Systematic reviews of radical prostatectomy—including robotic surgery—generally associate higher surgeon and hospital case volume with:
- fewer perioperative complications;
- shorter hospital stay;
- lower positive-margin rates in some analyses;
- lower need for additional treatment in some datasets;
- and better continence recovery on average.
However, volume is not a guarantee.
A national Swedish study found wide variation between surgeons and hospitals even within similar volume groups. Outcome measurement matters more than relying on case count alone.
What questions should a patient ask a robotic prostatectomy surgeon or centre?
Useful questions include:
- How many radical prostatectomies do you personally perform each year?
- What proportion are robotic, and how long have you used this platform?
- How do you define urinary continence in your published or audited outcomes?
- What are your continence rates at 3, 6 and 12 months?
- For men potent before surgery, how do you define erectile-function recovery?
- How do you decide bilateral, unilateral or non-nerve-sparing surgery?
- What are your positive-margin rates for pT2 disease separately from pT3 disease?
- What are your transfusion, readmission and major-complication rates?
- How often do patients require postoperative salvage radiation?
- Who manages continence and erectile rehabilitation after discharge?
- How quickly can I contact the team if there is a catheter, wound or urinary problem?
Why are definitions important when comparing centres?
A centre reporting “95% continent” may define continence as:
- zero pads;
- zero or one safety pad;
- no patient-reported bother;
- or another threshold.
Similarly, “potent” can mean spontaneous erections, erections with tablets, erections with injections or a questionnaire cutoff.
Numbers cannot be compared fairly until the definitions and patient population are the same.
Commercial claims should be converted into measurable clinical questions. “Advanced robot,” “precision surgery” and “high success rate” are incomplete statements unless the centre reports who was treated, how outcomes were defined, what stage the tumors were and how long patients were followed.
→Robotic Prostatectomy: What the Technology Changes and What It Does Not
| Feature | What robotic assistance can change | What it does not change |
|---|---|---|
| Surgical access | Uses small ports or a single-port platform instead of a large open incision. | The entire prostate still has to be removed. |
| Visualization | Provides magnified three-dimensional view of deep pelvic anatomy. | Cannot make tumor extension disappear or make unsafe nerve sparing safe. |
| Instrument movement | Wristed instruments and motion scaling improve dexterity in a confined space. | Does not replace surgeon judgment or experience. |
| Blood loss | Generally lower than open surgery. | Bleeding and transfusion remain possible. |
| Hospital recovery | Often shorter hospital stay and faster early physical recovery. | Catheter, urinary reconstruction and functional recovery remain necessary. |
| Continence | May improve early recovery in some trials and techniques. | Does not guarantee pad-free continence. |
| Erections | Can facilitate precise nerve-sparing dissection when oncologically appropriate. | Cannot guarantee erectile recovery or preserve nerves invaded by cancer. |
| Cancer control | Can deliver high-quality radical prostatectomy in experienced hands. | Long-term outcome still depends on stage, grade, margins, nodes, PSA and biology. |
Key Points
- Robotic prostatectomy is robot-assisted radical prostatectomy, not a separate cancer-removal operation.
- The surgeon controls the robotic system throughout the procedure.
- The robotic platform provides magnified three-dimensional visualization, articulated instruments, tremor filtration and motion scaling.
- Most procedures use multiple small ports; single-port platforms are also available.
- Pneumoperitoneum and Trendelenburg positioning create surgical workspace but introduce their own anesthetic and positioning considerations.
- The prostate and usually seminal vesicles are still removed, and the bladder is still reconnected to the urethra.
- Robotic surgery should only be considered after the patient has first been shown to be an appropriate candidate for radical prostatectomy.
- A minimally invasive approach does not justify unnecessary treatment of low-risk prostate cancer.
- The most consistent advantages over open surgery are less blood loss, fewer transfusions and shorter hospital stay.
- Some studies show faster early continence or erectile recovery, but long-term functional differences are less consistent.
- Robot assistance does not guarantee negative margins, urinary continence or erectile function.
- Nerve sparing remains a side-specific oncological decision.
- Single-port and multi-port robotic surgery have broadly comparable functional and oncological outcomes in current evidence, with some perioperative differences.
- The brand of robotic platform should not be treated as a substitute for surgeon skill or measured outcomes.
- Higher surgeon and hospital case volume is associated with better results on average, but outcome variation remains even among similarly high-volume providers.
- Patients comparing programs should ask for clearly defined continence, potency, complication, margin, PSA and salvage-treatment outcomes.
- After surgery, final pathology and postoperative PSA—not the robotic platform—determine whether surveillance or additional treatment is needed.
Clinical bottom line: robot-assisted prostatectomy is a sophisticated minimally invasive way to perform radical prostatectomy, but it should not be confused with an autonomous operation or a guarantee of better cancer control. The clearest advantages are reduced blood loss, lower transfusion requirements and shorter hospitalization compared with open surgery. Some evidence also supports faster early continence and erectile recovery, although long-term differences are smaller and less consistent. The most important determinants of outcome remain whether surgery was appropriate in the first place, the cancer’s stage and biology, the quality of nerve-sparing and reconstructive technique, surgeon and centre performance, final surgical margins and postoperative PSA. A patient comparing robotic programs should therefore compare audited clinical outcomes—not simply the availability or brand of a surgical robot.
Medical disclaimer: This article provides general medical education about robot-assisted radical prostatectomy. Surgical candidacy, access route, nerve sparing, lymph-node dissection, anesthetic suitability, recovery, continence, erectile function and cancer outcomes vary according to stage, Grade Group, PSA, MRI, anatomy, prior surgery, health, medications, surgeon experience and institutional practice. Individual decisions require consultation with the treating urologic oncology and anesthesia teams.
For the overall management framework, return to Prostate Cancer Treatment. For the underlying cancer operation, review Radical Prostatectomy for Prostate Cancer. The next guide covers Radiation Therapy for Prostate Cancer, the major non-surgical curative local-treatment pathway. Long-term recovery and cancer follow-up are covered in Prostate Cancer Survivorship. For the broader disease framework, return to the Prostate Cancer hub.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: robot-assisted radical prostatectomy technique, pneumoperitoneum, postoperative complications, continence, erectile function, nerve sparing, reconstruction and comparison with open/laparoscopic surgery.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Health Professional Version: robot-assisted versus open prostatectomy, randomized functional-outcome evidence and radical-prostatectomy complications.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Patient Version: patient-facing description of robot-assisted laparoscopic radical prostatectomy and major surgical adverse effects.
- 2026 systematic review and meta-analysis — prospective and randomized comparisons of robot-assisted versus open radical prostatectomy, including perioperative, functional and oncological outcomes.
- 2025 meta-analysis — single-port versus multi-port robot-assisted radical prostatectomy, including perioperative recovery, continence, potency and oncological outcomes.
- European Urology Focus — comparative evidence for Hugo RAS versus da Vinci robotic platforms, showing broadly comparable early perioperative, functional and oncological outcomes.
- European Urology systematic review — relationship between surgeon/hospital caseload and radical-prostatectomy oncological and non-oncological outcomes.
